Stefan Oschmann, EFPIA President, Chairman of the Executive Board and CEO of Merck

Since the UK public voted to leave the European Union, the potential impact on our healthcare systems has begun to loom large. For most sectors, the issues around Brexit are economic. But medicines are different. As the research-based pharmaceutical industry, the medicines we make improve the quality of life, often save the lives of patients in the UK and across Europe. For us, the primary concern around Brexit has always been patient safety and public health, in particular the uninterrupted supply of medicines to patients in the 27 EU Member States and the United Kingdom.